Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol 2002;187:116-26
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000;6:S565-73
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, et al. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol 2008;53:1029-37
   PubMed Web of Science ®Google Scholar
• Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001;98:398-406
   PubMed Web of Science ®Google Scholar
• Macdiarmid SA. Maximizing the treatment of overactive bladder in the elderly. Rev Urol 2008;10:6-13
   PubMedGoogle Scholar
• McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001;7:S62-75
   PubMed Web of Science ®Google Scholar
• Gentili A, Weiner DK, Kuchibhatil M, et al. Factors that disturb sleep in nursing home residents. Aging (Milano) 1997;9:207-13
   PubMedGoogle Scholar
• Neubauer DN. Sleep problems in the elderly. Am Fam Physician 1999;59:2551-8, 9-60
   PubMed Web of Science ®Google Scholar
• Stone KL, Ancoli-Israel S, Blackwell T, et al. Actigraphy-measured sleep characteristics and risk of falls in older women. Arch Intern Med 2008;168:1768-75
   PubMedGoogle Scholar
• Stone KL, Ensrud KE, Ancoli-Israel S. Sleep, insomnia and falls in elderly patients. Sleep Med 2008;9(Suppl 1):S18-22
   PubMed Web of Science ®Google Scholar
• Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000;48:721-5
   PubMed Web of Science ®Google Scholar
• Kraus SR, Bavendam T, Brake T, et al. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging 2010;27:697-713
   PubMed Web of Science ®Google Scholar
• Wolff GF, Kuchel GA, Smith PP. Overactive bladder in the vulnerable elderly. Res Rep Urol 2014;6:131-8
   PubMedGoogle Scholar
• Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014;191:1003-8
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175:401-7
   PubMed Web of Science ®Google Scholar
• Pagoria D, O'Connor RC, Guralnick ML. Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr Urol Rep 2011;12:351-7
   PubMedGoogle Scholar
• Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001;19:299-306
   PubMed Web of Science ®Google Scholar
• Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur Urol 2003;43:1-5
   PubMed Web of Science ®Google Scholar
• Cetinel B, Onal B. Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol 2013;54:806-15
   PubMedGoogle Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Tack J, Wyndaele JJ, Ligozio G, et al. A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials. Drug Healthc Patient Saf 2012;4:127-39
   PubMedGoogle Scholar
• Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004;145:59-66
   PubMed Web of Science ®Google Scholar
• Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-8
   PubMed Web of Science ®Google Scholar
• Messer WS Jr, Bohnett M, Stibbe J. Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci Lett 1990;116:184-9
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Staskin DR, Kay GG, et al. Blood–brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging 2012;29:259-73
   PubMed Web of Science ®Google Scholar
• Kleine TO, Hackler R, Zofel P. Age-related alterations of the blood–brain-barrier (BBB) permeability to protein molecules of different size. Z Gerontol 1993;26:256-9
   PubMed Web of Science ®Google Scholar
• Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol 1993;33:129-33
   PubMed Web of Science ®Google Scholar
• Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood–cerebrospinal fluid barrier. Med Sci Monit 2000;6:314-18
   PubMedGoogle Scholar
• Blennow K, Wallin A, Fredman P, et al. Blood–brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 1990;81:323-6
   PubMed Web of Science ®Google Scholar
• Liebsch R, Kornhuber ME, Dietl D, et al. Blood–CSF barrier integrity in multiple sclerosis. Acta Neurol Scand 1996;94:404-10
   PubMed Web of Science ®Google Scholar
• Starr JM, Wardlaw J, Ferguson K, et al. Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003;74:70-6
   PubMed Web of Science ®Google Scholar
• Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15-28
   PubMed Web of Science ®Google Scholar
• Lowry E, Woodman RJ, Soiza RL, et al. Associations between the anticholinergic risk scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc 2011;12:565-72
   PubMed Web of Science ®Google Scholar
• Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011;59:1477-83
   PubMed Web of Science ®Google Scholar
• Koshoedo S, Soiza RL, Purkayastha R, et al. Anticholinergic drugs and functional outcomes in older patients undergoing orthopaedic rehabilitation. Am J Geriatr Pharmacother 2012;10:251-7
   PubMedGoogle Scholar
• Lowry E, Woodman RJ, Soiza RL, et al. Clinical and demographic factors associated with antimuscarinic medication use in older hospitalized patients. Hosp Pract (1995) 2011;39:30-6
   PubMedGoogle Scholar
• Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;43:604-15
   PubMed Web of Science ®Google Scholar
• Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med 2011;364:2227-34
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31
   PubMed Web of Science ®Google Scholar
• Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 2011;72:186-96
   PubMed Web of Science ®Google Scholar
• Walch L, Brink C, Norel X. The muscarinic receptor subtypes in human blood vessels. Thérapie 2001;56:223-6
   PubMed Web of Science ®Google Scholar
• Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005;48:471-7
   PubMed Web of Science ®Google Scholar
• Hill S, Elhilali M, Millard RJ, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007;23:2697-704
   PubMed Web of Science ®Google Scholar
• Sand PK, Johnson II TM, Rovner ES, et al. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome. BJU Int 2011;107:612-20
   PubMed Web of Science ®Google Scholar
• DuBeau CE, Morrow JD, Kraus SR, et al. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials. Neurourol Urodyn 2012;31:1258-65
   PubMed Web of Science ®Google Scholar
• Kraus SR, Ruiz-Cerdá JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010;76:1350-7
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Marschall-Kehrel D, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 2013;61:185-93
   PubMed Web of Science ®Google Scholar
• Wagg A, Khullar V, Michel MC, et al. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodyn 2014;33:106-14
   PubMed Web of Science ®Google Scholar
• Capo JP, Lucente V, Forero-Schwanhaeuser S, et al. Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. Postgrad Med 2011;123:94-104
   PubMed Web of Science ®Google Scholar
• Drinka PJ. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:292-3
   PubMedGoogle Scholar
• Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
   PubMedGoogle Scholar
• Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-10
   PubMedGoogle Scholar
• Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21
   PubMed Web of Science ®Google Scholar
• Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-65
   PubMed Web of Science ®Google Scholar
• Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012;62:1040-60
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317-26
   PubMed Web of Science ®Google Scholar
• Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients ≥65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007;23:2347-58
   PubMed Web of Science ®Google Scholar
• Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005;173:493-8
   PubMed Web of Science ®Google Scholar
• Dubeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol 2014;191:395-404
   PubMed Web of Science ®Google Scholar
• Lackner TE, Wyman JF, McCarthy TC, et al. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 2008;56:862-70
   PubMed Web of Science ®Google Scholar
• Aaron LE, Morris TJ, Jahshan P, et al. An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. Curr Med Res Opin 2012;28:1369-79
   PubMed Web of Science ®Google Scholar
• Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995;43:610-17
   PubMed Web of Science ®Google Scholar
• Herschorn S, Pommerville P, Stothers L, et al. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin 2011;27:375-82
   PubMed Web of Science ®Google Scholar
• Griebling TL, Kraus SR, Richter HE, et al. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 2009;63:1198-204
   PubMed Web of Science ®Google Scholar
• Szonyi G, Collas DM, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995;24:287-91
   PubMed Web of Science ®Google Scholar
• Wagg A, Dale M, Tretter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013;64:74-81
   PubMed Web of Science ®Google Scholar
• Schaefer W. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2007;14:670-1
   PubMed Web of Science ®Google Scholar
• Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44
   PubMed Web of Science ®Google Scholar
• Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One 2011;6:e16718
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Giannitsas K. An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 2011;2011:820816
   PubMedGoogle Scholar
• Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc 2002;50:535-43
   PubMed Web of Science ®Google Scholar
• Schaefer DC, Cheskin LJ. Constipation in the elderly. Am Fam Physician 1998;58:907-14
   PubMed Web of Science ®Google Scholar
• Rosenberg MT, Newman DK, Tallman CT, et al. Overactive bladder: recognition requires vigilance for symptoms. Cleve Clin J Med 2007;74(Suppl 3):S21-9
   PubMedGoogle Scholar
• Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005;27:127-38
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
   PubMed Web of Science ®Google Scholar
• Miller DW, Hinton M, Chen F. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood–brain and blood–ocular barriers. Neurourol Urodyn 2011;30:1633-8
   PubMed Web of Science ®Google Scholar
• Kerdraon J, Robain G, Jeandel C, et al. [Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly]. Prog Urol 2014;24:672-81
   PubMed Web of Science ®Google Scholar
• Malhotra B, Gandelman K, Sachse R, et al. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009;16:4481-9
   PubMed Web of Science ®Google Scholar
• Wesnes KA, Edgar C, Tretter RN, et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf 2009;8:615-26
   PubMed Web of Science ®Google Scholar
• Hampel C, Burger M, Buerger K, et al. Effect of solifenacin on cognition in geriatric patients: results of the non-interventional study vesicare in geriatric application: VEGA. Urology 2012;80(Suppl 3A):Abstr. POD-03.4
   Google Scholar
• Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13
   PubMed Web of Science ®Google Scholar
• Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ 1997;315:1363-4
   PubMed Web of Science ®Google Scholar
• Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005;27:144-53
   PubMed Web of Science ®Google Scholar
• Williams SG, Staudenmeier J. Hallucinations with tolterodine. Psychiatr Serv 2004;55:1318-19
   PubMed Web of Science ®Google Scholar
• Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003;349:2274-5
   PubMed Web of Science ®Google Scholar
• Malavaud B, Bagheri H, Senard JM, et al. Visual hallucinations at the onset of tolterodine treatment in a patient with a high-level spinal cord injury. BJU Int 1999;84:1109
   PubMed Web of Science ®Google Scholar
• Štuhec M. Solifenacin-induced delirium and hallucinations. Gen Hosp Psychiatry 2013;35:682.e3-4
   PubMed Web of Science ®Google Scholar
• Sand PK, Rovner ES, Watanabe JH, et al. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging 2011;28:151-60
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010;64:1294-300
   PubMed Web of Science ®Google Scholar
• Pietzko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994;47:337-43
   PubMed Web of Science ®Google Scholar
• Oelke M, Murgas S, Schneider T, Heßdörfer E. Influence of propiverine ER 30 mg once daily on cognitive function in elderly female and male patients with overactive bladder: a non-interventional study to assess real life data. International Continence Society, 2013, Barcelona, Spain: A210
   Google Scholar
• Rosa GM, Bauckneht M, Scala C, et al. Cardiovascular effects of antimuscarinic agents in overactive bladder. Expert Opin Drug Saf 2013;12:815-27
   PubMed Web of Science ®Google Scholar
• Zinner N, Noe L, Rasouliyan L, et al. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. Am J Geriatr Pharmacother 2009;7:373-82
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188:2455-63
   PubMed Web of Science ®Google Scholar
• Tincello DG, Adams EJ, Sutherst JR, et al. Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of a multicentre, randomized controlled trial. BJU Int 2000;85:416-20
   PubMed Web of Science ®Google Scholar
• Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manage Care Pharm 2009;15:728-40
   PubMed Web of Science ®Google Scholar
• Wagg A, Franks B, Ramos B, et al. Persistence and adherence with mirabegron, a new beta-3 receptor agonist, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J 2015;9:343-50
   PubMed Web of Science ®Google Scholar
• Nitti V, Rovner E, Franks B, et al. Persistence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits; In Press 2016
   Web of Science ®Google Scholar
• Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88-119
   PubMed Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473-81
   PubMed Web of Science ®Google Scholar
• Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology 2002;59:25-9
   PubMed Web of Science ®Google Scholar
• Wuest M, Eichhorn B, Grimm MO, et al. Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man. J Pharmacol Exp Ther 2009;328:213-22
   PubMed Web of Science ®Google Scholar
• Andersson KE. Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 2009;1:71-83
   PubMedGoogle Scholar
• Leon LA, Hoffman BE, Gardner SD, et al. Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats. J Pharmacol Exp Ther 2008;326:178-85
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V. Mirabegron, a β3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010;13:713-22
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012;62:834-40
   PubMed Web of Science ®Google Scholar
• Maruyama I, Goi Y, Tatemichi S, et al. Bladder selectivity of the novel β3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat. Naunyn Schmiedebergs Arch Pharmacol 2012;385:845-52
   PubMed Web of Science ®Google Scholar
• Maruyama I, Tatemichi S, Goi Y, et al. Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther 2012;342:163-8
   PubMed Web of Science ®Google Scholar
• Kanie S, Otsuka A, Yoshikawa S, et al. Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips. Urology 2012;79:744 e1-7
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Betmiga. Committee for Medicinal Products for Human Use (CHMP), 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002388/WC500137308.pdf [Last accessed 19 November 2015]
   Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 2014;33:17-30
   PubMed Web of Science ®Google Scholar
• Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol 2016;69:311–23
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305
   PubMed Web of Science ®Google Scholar
• Wagg A, Cardozo L, Nitti VW, et al. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing 2014;43:666-75
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276-82
   PubMed Web of Science ®Google Scholar
• Krief S, Lonnqvist F, Raimbault S, et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 1993;91:344-9
   PubMed Web of Science ®Google Scholar
• Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999;51:651-90
   PubMed Web of Science ®Google Scholar
• Skeberdis VA, Gendviliene V, Zablockaite D, et al. Beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current. J Clin Invest 2008;118:3219-27
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Global Development Inc. Advisory committee briefing document. Mirabegron (YM178) for the treatment of overactive bladder. 2012. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM298285.pdf [Last accessed 19 November 2015]
   Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 2013;67:619-32
   PubMed Web of Science ®Google Scholar
• Herschorn S, Kowey P, Nitti V, et al. Cardiovascular assessments in short- and long-term phase 3 mirabegron trials in patients with OAB. Eur Urol Suppl 2013;12:e739-40
   Google Scholar
• Astellas Pharma Inc. Prescribing information for Myrbetriq (mirabegron) extended-release tablets, for oral use. Revised 2015. Available at: http://www.us.astellas.com/docs/Myrbetriq_WPI.pdf [Last accessed September 2015]
   Google Scholar
• Klarskov P, Andersen JT, Asmussen CF, et al. Symptoms and signs predictive of the voiding pattern after acute urinary retention in men. Scand J Urol Nephrol 1987;21:23-8
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7
   PubMed Web of Science ®Google Scholar
• Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 1999;162:376-82
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Abrams P, et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract 2011;65:487-507
   PubMed Web of Science ®Google Scholar
• Martin-Merino E, Garcia-Rodriguez LA, Masso-Gonzalez EL, et al. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009;182:1442-8
   PubMed Web of Science ®Google Scholar
• Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol 2013;190:1320-7
   PubMed Web of Science ®Google Scholar
• Eskandar OS, Eckford SD, Whittaker KW. Treatment of overactive bladder (OAB) with anti-cholinergic drugs and the risk of glaucoma. J Obstet Gynaecol 2005;25:419-21
   PubMedGoogle Scholar
• Kato K, Furuhashi K, Suzuki K, et al. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol 2007;14:595-7
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA 2014;311:1901-11
   PubMed Web of Science ®Google Scholar
• Novack GD, Lewis RA, Vogel R, et al. Randomized, double-masked, placebo-controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther 2013;29:674-80
   PubMed Web of Science ®Google Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
   PubMed Web of Science ®Google Scholar
• Wagg A, Nitti V, Kelleher C, et al. Effects of the β3-adrenoceptor agonist, mirabegron, on quality of life in older patients with overactive bladder: a post-hoc analysis of pooled data from 3 randomised phase 3 trials. J Urol 2014;191:e339
   Web of Science ®Google Scholar
• Lipsitz D, Frankel J, Berner T, et al. Evaluating the magnitude of improvements in patient-reported outcomes by age in overactive bladder patients: a pooled analysis of two mirabegron clinical trials. International Continence Society, 44th Annual Meeting, 2014, Rio de Janeiro, Brazil: Abstract 579
   Google Scholar
• Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: Report from the 5th International Consultation on Incontinence. Neurourol Urodyn 2015;34:398-406
   PubMed Web of Science ®Google Scholar
• Inouye SK, Studenski S, Tinetti ME, et al. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 2007;55:780-91
   PubMed Web of Science ®Google Scholar
• Samuelsson E, Odeberg J, Stenzelius K, et al. Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: a systematic review. Geriatr Gerontol Int 2015;15:521-34
   PubMed Web of Science ®Google Scholar
• Lackner TE, Wyman JF, McCarthy TC, et al. Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial. J Am Med Dir Assoc 2011;12:639-47
   PubMed Web of Science ®Google Scholar
• Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 2015;44:745-55
   PubMed Web of Science ®Google Scholar